SD-208

SD-208 is a potent, orally bioavailable small molecule inhibitor of the Transforming Growth Factor-beta receptor type 1 (TGFBR1), also known as Activin receptor-like kinase 5 (ALK5). It acts as an ATP-competitive kinase inhibitor, blocking the phosphorylation of downstream SMAD proteins and thereby inhibiting the canonical TGF-β signaling pathway. Developed by Scios Inc. (later acquired by Johnson & Johnson), SD-208 has been extensively utilized as a pharmacological tool in preclinical research to investigate the role of TGF-β in cancer progression, epithelial-mesenchymal transition (EMT), and fibrosis. In oncology models, SD-208 has demonstrated the ability to inhibit tumor growth, metastasis, and angiogenesis, particularly in gliomas, prostate cancer, and pancreatic cancer. It is notably recognized for its ability to modulate the tumor microenvironment and enhance anti-tumor immune responses.

Other names

2-(5-chloro-2-fluorophenyl)-4-[(4-pyridyl)amino]pteridine